FDA approves Swiss dermatological company Galderma’s AKLIEF acne cream
Category: #health  By Saipriya Iyer  Date: 2019-10-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

FDA approves Swiss dermatological company Galderma’s AKLIEF acne cream

Skin care is one of the fastest growing concerns of the modern generation and acne is the foremost issue many face in their day-to-day lives. Global pharmaceutical firms are increasingly working towards finding treatments for skin care and reduce acne issues for people.

Galderma S.A., a renowned Swiss pharmaceutical firm specializing in the development, research and marketing of dermatological therapies, reportedly announced that the United States Food and Drug Administration (FDA) granted approval to its AKLIEF® Cream (trifarotene), 0.005% for acne’s topical treatment.

AKLIEF Cream is a unique topical retinoid that targets RAR (retinoic acid receptor) gamma, the RAR that is most commonly found in the skin, selectively. Trifarotene is now the first novel retinoid molecule, which has received U.S. FDA approval to treat acne, since the last 20 years.

AKLIEF Cream is the first and only topical therapy that has been specifically studied and proven for the treatment of facial (chin, nose, cheeks and forehead) as well as truncal (back, shoulders and chest) acne, providing acne patients and healthcare professionals another option for acne treatment.

The AKLIEF Cream approval by FDA is supported by data received from two pivotal Phase 3 clinical studies of daily-once AKLIEF Cream applied on patients having moderate acne on the trunk and face.    

An investigator at the clinical studies of AKLIEF Cream as well as a dermatologist at the Johnson Dermatology in Fort Smith, Arkansas, Sandra Johnson, M.D., FAAD, stated that retinoids are foundational treatments to treat acne, but there has been very little innovation in this field in decades. 

Johnson added that with the FDA approval for AKLIEF Cream, it would be quite thrilling to offer the patients a highly targeted, unique retinoid that decreases inflammatory lesions that occur on the back, face, shoulders and chest, and that has also been proven to be well-tolerated and safe.

AKLIEF Cream would be available across the United States by November 2019. The cream would be provided in a pump of 45 gram. Also, Galderma is closely working with providers, payers and pharmacy benefit managers in an effort to ensure rapid and broad access to AKLIEF C ream.

Additionally, the pharmaceutical firm would also give a patient savings card program named as Galderma CareConnect to uninsured or commercially insured patients.

 

Source credit: https://www.galderma.com/us/news/galderma-receives-fda-approval-akliefr-trifarotene-cream-0005-first-new-retinoid-molecule



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Foodics enters Egypt market by setting an on-ground presence in Cairo
Foodics enters Egypt market by setting an on-ground presence in Cairo
By Saipriya Iyer

Saudi Arabia-based restaurant management platform Foodics, has announced that it has entered the Egyptian market by creating an on-the-ground presence in Cairo.  The expansion comes after the company raised USD 4 ...

Food Emulsifiers Market to Witness an Appreciable Growth By 2026
Food Emulsifiers Market to Witness an Appreciable Growth By 2026
By Saipriya Iyer

This advanced report on the Food Emulsifiers Market includes of an in-depth overview of this business sphere. Alongside, details of the present market size and status have been given. The report aims to provide substantial updates on the market, p...

Bharat Biotech reveals positive data from animal trial of Covaxin
Bharat Biotech reveals positive data from animal trial of Covaxin
By Saipriya Iyer

Bharat Biotech, an Indian biotechnology company, has reportedly revealed positive results from the animal trial of Covaxin, India’s COVID-19 vaccine candidate.

In the animal t...